Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aortic endografts (EVAR/TEVAR) cases in Louisiana: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 10% on average (139 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 261 | 42% |
| 2020 | 1 | 219 | 45% |
| 2021 | 1 | 172 | 51% |
| 2022 | 1 | 204 | 54% |
| 2023 | 1 | 168 | 58% |
| 2024 | 0 | 167 | 60% |
| 2025 from claims | – | 145 117–171 | 61% |
| 2026 forecast | – | 144 113–181 | 62% |
| 2027 forecast | – | 143 106–189 | 63% |
| 2028 forecast | – | 142 101–197 | 63% |
| 2029 forecast | – | 142 96–203 | 64% |
| 2030 forecast | – | 141 92–209 | 65% |
Endovascular abdominal and thoracic aortic repair. Professional codes (what the surgeon bills): CPT 34701, 34702, 34703, 34704, 34705, 34706, 33880, 33881; the hospital bills MS-DRG 268, 269, 213, 209.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
No metro breakdown yet.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 10 | 1,226−4.3%/yr | −4.3%/yr | 0.6 | 0% | 1,210 in 2030−0.2%/yr |
| Texas | 3 | 1,065−5.8%/yr | −5.8%/yr | 0.5 | 0% | 1,150 in 2030+1.3%/yr |
| North Carolina | 3 | 449−8.3%/yr | −8.3%/yr | 0.5 | 0% | 420 in 2030−1.1%/yr |
| Virginia | 3 | 443−6.2%/yr | −6.2%/yr | 0.4 | 0% | 440 in 2030−0.2%/yr |
| Georgia | 2 | 405−5.4%/yr | −5.4%/yr | 0.5 | 0% | 450 in 2030+1.8%/yr |
| Tennessee | 2 | 345−9.6%/yr | −9.6%/yr | 0.5 | 0% | 400 in 2030+2.4%/yr |
| Maryland | 2 | 330−2.9%/yr | −2.9%/yr | 0.4 | 0% | 400 in 2030+3.3%/yr |
| Kentucky | 2 | 285−10%/yr | −10%/yr | 0.6 | 0% | 280 in 2030−0.3%/yr |
| South Carolina | 0 | 274−8.3%/yr | −8.3%/yr | 0.4 | 0% | 250 in 2030−1.7%/yr |
| Alabama | 2 | 218−11%/yr | −11%/yr | 0.5 | 0% | 230 in 2030+1%/yr |
| Arkansas | 6 | 201−3.4%/yr | −3.4%/yr | 0.5 | 0% | 170 in 2030−3.1%/yr |
| Oklahoma | 3 | 167−14%/yr | −14%/yr | 0.3 | 0% | 190 in 2030+2.3%/yr |
| Mississippi | 2 | 121−7.9%/yr | −7.9%/yr | 0.3 | 0% | 130 in 2030+1.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral arterial intervention | 12 | 2,691−14%/yr | −14%/yr | 6.31.0× | 32% | 2,760 in 2030+0.4%/yr |
| Dialysis access | 35 | 2,265−18%/yr | −18%/yr | 5.81.1× | 26% | 2,030 in 2030−1.8%/yr |
| Superficial venous ablation | 25 | 1,654−4.9%/yr | −4.9%/yr | 3.80.6× | 99% | 1,580 in 2030−0.8%/yr |
| Carotid revascularization | 17 | 665−8.6%/yr | −8.6%/yr | 1.61.2× | 0% | 580 in 2030−2.4%/yr |
| Thrombectomy, IVC filters & venous stents | 4 | 589−13%/yr | −13%/yr | 1.50.8× | 0% | 560 in 2030−0.8%/yr |
Aortic endografts (EVAR/TEVAR) in every state, and its device makers · Every procedure market in Louisiana · Every state · Compare with Florida
Medtronic leads with 40% of company spending on these surgeons in 2025, −16 pts on 2024.
In 2025, 5 companies reported engagement with Louisiana’s surgeons worth $33K in consulting, speaking, meals and travel tied to these products. Royalties are left out.
FDA, last 12 months: 36 clearances and approvals in the category, 2 recalled product lines (1 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.